A B C D E F G H I J K L M N O P Q R S T U V W X Y Z   <<  >>

Terms for subject Medical (3308 entries)

JRA	juvenile rheumatoid arthritis	alia20
JZ	junctional zone	'More
Juvenile Arthritis Matters	JAM
JRA	juvenile rheumatoid arthritis	alia20
JZ	junctional zone	'More
Kaiser	kaiser
Kaiser	kaiser
Kaletra	ABT378
Kansas Heart Hospital	KHH
Kansas Hospital Association	KHA
Kansas Hospital Board	KHB
kaodzera	Kaodzera
Kaposi sarcoma (KS)	A rare type of cancer characterized by the abnormal growth of cells that line lymph and blood vessels. Kaposi sarcoma (KS) causes red or purple patches of tissue (lesions) to grow under the skin and in the lining of the mouth, nose, and throat. Lesions may also develop in the digestive tract, liver, or lungs. KS generally occurs in people with weakened immune systems. In people with HIV, KS is an AIDS-defining condition.
Kaposi sarcoma (KS)	A rare type of cancer characterized by the abnormal growth of cells that line lymph and blood vessels. Kaposi sarcoma (KS) causes red or purple patches of tissue (lesions) to grow under the skin and in the lining of the mouth, nose, and throat. Lesions may also develop in the digestive tract, liver, or lungs. KS generally occurs in people with weakened immune systems. In people with HIV, KS is an AIDS-defining condition.
Kaposi sarcoma herpesvirus (KSHV)	A type of herpesvirus that causes Kaposi sarcoma. Kaposi sarcoma herpesvirus (KSHV) is primarily transmitted through genital fluids and saliva. Most people infected with KSHV do not develop Kaposi sarcoma. In people with weakened immune systems, including people with HIV, the viral infection is much more likely to advance to Kaposi sarcoma than in people with healthy immune systems.
Kaposi sarcoma herpesvirus (KSHV)	A type of herpesvirus that causes Kaposi sarcoma. Kaposi sarcoma herpesvirus (KSHV) is primarily transmitted through genital fluids and saliva. Most people infected with KSHV do not develop Kaposi sarcoma. In people with weakened immune systems, including people with HIV, the viral infection is much more likely to advance to Kaposi sarcoma than in people with healthy immune systems.
Karnofsky Performance Status	A way to rate a person's ability to perform activities of daily living. The Karnofsky performance status is used to evaluate whether a person should receive a therapy, whether a therapy should be adjusted or discontinued, and whether a person may participate in a clinical trial. The scores range from 0 to 100, with a higher score indicating that a person is better able to perform daily activities.
Karnofsky Performance Status	A way to rate a person's ability to perform activities of daily living. The Karnofsky performance status is used to evaluate whether a person should receive a therapy, whether a therapy should be adjusted or discontinued, and whether a person may participate in a clinical trial. The scores range from 0 to 100, with a higher score indicating that a person is better able to perform daily activities.
Karnofsky score	A way to rate a person's ability to perform activities of daily living. The Karnofsky performance status is used to evaluate whether a person should receive a therapy, whether a therapy should be adjusted or discontinued, and whether a person may participate in a clinical trial. The scores range from 0 to 100, with a higher score indicating that a person is better able to perform daily activities.
Karnofsky score	A way to rate a person's ability to perform activities of daily living. The Karnofsky performance status is used to evaluate whether a person should receive a therapy, whether a therapy should be adjusted or discontinued, and whether a person may participate in a clinical trial. The scores range from 0 to 100, with a higher score indicating that a person is better able to perform daily activities.